VERSES AI’s Credibility Craters as Karl Friston and Top Executives Walk Out, Trading Halted
28.06.2026 - 16:23:01 | boerse-global.de
The scientific foundation of VERSES AI has disintegrated. Karl Friston, the globally recognized neuroscientist who built the theoretical underpinnings of the company’s “Genius” platform through his work on active inference, resigned as Chief Science Officer on June 27, 2026. His departure, along with that of President and COO James Hendrickson and CTO Hari Thiruvengada on the same day, leaves the Canadian company stripped of both its leadership and its last shred of scientific credibility.
Hendrickson and Thiruvengada cited fundamental conflicts with the board as their reason for leaving, including what they claimed were unpaid employee wages. The entire management exodus came just days after VERSES AI announced it was shutting down all artificial intelligence operations — a complete reversal from its earlier identity as a high-flying AI hopeful.
A Business Unraveling
The retreat from AI had immediate contractual consequences. VERSES terminated its license agreement with Prodigii AI, a deal signed only in April 2026 that was supposed to generate an upfront payment of $350,000 and quarterly installments of $125,000 over ten years. It also dissolved a partnership with an unnamed global investment house that the company had previously described as central to integrating the Genius platform into institutional risk management.
Interim CEO David T. Scott explained that the decision to cease operations followed four months of failed attempts to raise capital. Equity raises, mergers, asset sales — none succeeded. The company now says it is exploring “strategic alternatives” without offering any concrete new business model.
Should investors sell immediately? Or is it worth buying VERSES AI?
Bleeding Red Ink
The financial realities are stark. For fiscal 2026, VERSES AI posted a net loss of roughly $43 million, an improvement over the prior year’s $52 million deficit only in the sense that the numbers are marginally smaller. Revenue came in at just $155,000. The gross margin was negative 307% — a clear indication that the cost of generating those meager sales far outstripped any return.
The stock market had already passed judgment long before the suspension. By the time Cboe Canada halted trading for a regulatory review, the shares had fallen to C$0.60. In Frankfurt, the last trade was €0.202. Over the preceding 12 months, the stock had lost more than 96% of its value, sliding from a 52-week high of C$24.48. The market capitalization had shrunk to roughly C$3.7 million at the last trade in Canada.
The 90-Day Clock
Cboe Canada has launched a 90-day review period that runs through mid-September. VERSES AI must demonstrate that it still meets the exchange’s listing requirements. Without a concrete merger, acquisition, or fresh capital injection, that hurdle looks insurmountable. The company itself has warned that no rescue transaction may materialize.
VERSES AI at a turning point? This analysis reveals what investors need to know now.
Until a deal emerges, retail investors cannot trade the stock. The once-promising AI pioneer now faces an existential deadline, with its scientific star gone, its revenue negligible, and its cash register empty. Whether the 90-day review leads to a revival or a delisting remains entirely uncertain.
Ad
VERSES AI Stock: New Analysis - 28 June
Fresh VERSES AI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
